ADP-ribosylation of rab proteins by exoenzyme S (Exo S) of P. aeruginosa was studied using reticulocytes. 14-3-3 protein, the eukaryotic cofactor that is obligatory for Exo S activity, was found in association with reticulocyte endocytic vesicles and exosomes, vesicles previously shown to be enriched with rab4. Incubation of purified endocytic vesicles with Exo S triggered rab4 ADP-ribosylation. Transferrin recycling in SLO-permeabilized reticulocytes was highly impaired when Exo S was added to the cells, suggesting that ADP-ribosylation affected rab4 function. Moreover, in vitro ADP-ribosylation of different rab proteins was studied using the cofactor activity extracted from reticulocytes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1006/bbrc.1998.8263 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification of a novel Eps 15 homology domain-containing protein 1 (EHD1) and EHD4-binding motif in phostensin.
J Biochem
January 2025
Department of Biomedical Sciences, National Chung Cheng University, Chia Yi 621, Taiwan.
Phostensin (PTS) encoded by KIAA1949 binds to protein phosphatase 1, F-actin, Eps 15 homology domain-containing protein 1 (EHD1) and EHD4. Most EHD-binding proteins contain a consensus motif, Asn-Pro-Phe (NPF), which interacts with the C-terminal EH domain of EHD proteins. Nevertheless, the NPF motif is absent in PTS.
View Article and Find Full Text PDFThe PvRBP2b-TfR1 interaction is not essential for reticulocytes invasion by Plasmodium vivax isolates from Cambodia.
NPJ Vaccines
November 2024
Malaria Research Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.
Plasmodium vivax is the most widespread of the different Plasmodium species able to infect humans and is responsible for most malaria cases outside Africa. An effective, strain-transcending vaccine that alleviates or suppresses erythrocyte invasion would be a game-changer in eliminating vivax malaria. Recently, the binding of P.
View Article and Find Full Text PDFCYpHER: catalytic extracellular targeted protein degradation with high potency and durable effect.
Nat Commun
October 2024
Cyclera Therapeutics Inc, Seattle, WA, 98115, USA.
Article Synopsis
- - TPD can effectively eliminate disease-causing proteins by engaging a cell’s protein degradation system, overcoming limitations of traditional inhibitors that typically target only one mechanism.
- - The CYpHER technology utilizes a pH-dependent release system and a rapidly cycling transferrin receptor to enhance the delivery of therapeutic agents to surface and extracellular targets, increasing treatment potency while potentially reducing side effects.
- - Successful application of CYpHER was demonstrated both in laboratory settings (in vitro) with specific cancer markers (EGFR and PD-L1) and in animal studies (in vivo) using a model of lung cancer driven by EGFR.
CCDC158: A novel regulator in renal proximal tubular endocytosis unveiled through exome sequencing and interactome analysis.
J Cell Physiol
December 2024
Laboratory of Pediatric Nephrology, Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Article Synopsis
- The study investigates the role of a protein called CCDC158 in kidney function, specifically in the reabsorption of proteins in the renal proximal tubules, highlighting its importance in kidney and reproductive health.
- Whole exome sequencing identified a missense variant in CCDC158 in a male patient with kidney issues, which also appeared in a sister with similar symptoms, suggesting a hereditary component.
- Functional analyses showed that CCDC158 likely interacts with other proteins involved in endocytosis, affecting kidney function and contributing to conditions like proteinuria and oligospermia, but further research is needed to clarify its exact mechanisms.
CCT3/ACTN4/TFRC axis protects hepatocellular carcinoma cells from ferroptosis by inhibiting iron endocytosis.
J Exp Clin Cancer Res
August 2024
Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310000, Zhejiang, China.
Article Synopsis
- Sorafenib is a common treatment for advanced hepatocellular carcinoma (HCC), but its effectiveness is often reduced due to drug resistance.
- A study integrating posttranslational modification analysis and CRISPR screening discovered that ubiquitination of CCT3 plays a key role in this resistance.
- Targeting the CCT3/ACTN4/TFRC pathway may improve treatment outcomes by enhancing ferroptosis and overcoming resistance to Sorafenib in HCC patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!